Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
Saved in:
| Title: | Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials. |
|---|---|
| Authors: | Bender Ignacio RA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington., Chew KW; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles)., Moser C; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Currier JS; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles)., Eron JJ; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill., Javan AC; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland., Giganti MJ; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Aga E; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Gibbs M; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Tchouakam Kouekam H; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Toronto, Ontario, Canada., Johnsson E; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Esser MT; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Hoover K; Miami Clinical Research and Baptist Health South Florida, Miami., Neytman G; Quantum Clinical Trials, Miami Beach, Florida., Newell M; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill., Daar ES; Division of HIV Medicine, Lundquist Institute, Harbor-UCLA Medical Center, Los Angeles, California., Fischer W; Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina School of Medicine, Chapel Hill., Fletcher CV; UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha., Li JZ; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, Massachusetts., Greninger AL; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle., Coombs RW; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle., Hughes MD; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Smith D; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego., Wohl DA; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill. |
| Corporate Authors: | Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)–2/A5401 Study Team |
| Source: | JAMA network open [JAMA Netw Open] 2023 Apr 03; Vol. 6 (4), pp. e2310039. Date of Electronic Publication: 2023 Apr 03. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37099295 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Bender+Ignacio+RA%22">Bender Ignacio RA</searchLink>; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Chew+KW%22">Chew KW</searchLink>; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles).<br /><searchLink fieldCode="AU" term="%22Moser+C%22">Moser C</searchLink>; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Currier+JS%22">Currier JS</searchLink>; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles).<br /><searchLink fieldCode="AU" term="%22Eron+JJ%22">Eron JJ</searchLink>; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill.<br /><searchLink fieldCode="AU" term="%22Javan+AC%22">Javan AC</searchLink>; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Giganti+MJ%22">Giganti MJ</searchLink>; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Aga+E%22">Aga E</searchLink>; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Gibbs+M%22">Gibbs M</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Tchouakam+Kouekam+H%22">Tchouakam Kouekam H</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Johnsson+E%22">Johnsson E</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Esser+MT%22">Esser MT</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Hoover+K%22">Hoover K</searchLink>; Miami Clinical Research and Baptist Health South Florida, Miami.<br /><searchLink fieldCode="AU" term="%22Neytman+G%22">Neytman G</searchLink>; Quantum Clinical Trials, Miami Beach, Florida.<br /><searchLink fieldCode="AU" term="%22Newell+M%22">Newell M</searchLink>; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill.<br /><searchLink fieldCode="AU" term="%22Daar+ES%22">Daar ES</searchLink>; Division of HIV Medicine, Lundquist Institute, Harbor-UCLA Medical Center, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Fischer+W%22">Fischer W</searchLink>; Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina School of Medicine, Chapel Hill.<br /><searchLink fieldCode="AU" term="%22Fletcher+CV%22">Fletcher CV</searchLink>; UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha.<br /><searchLink fieldCode="AU" term="%22Li+JZ%22">Li JZ</searchLink>; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Greninger+AL%22">Greninger AL</searchLink>; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle.<br /><searchLink fieldCode="AU" term="%22Coombs+RW%22">Coombs RW</searchLink>; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle.<br /><searchLink fieldCode="AU" term="%22Hughes+MD%22">Hughes MD</searchLink>; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Smith+D%22">Smith D</searchLink>; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego.<br /><searchLink fieldCode="AU" term="%22Wohl+DA%22">Wohl DA</searchLink>; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22Accelerating+COVID-19+Therapeutic+Interventions+and+Vaccines+%28ACTIV%29–2%2FA5401+Study+Team%22">Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)–2/A5401 Study Team</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101729235%22">JAMA network open</searchLink> [JAMA Netw Open] 2023 Apr 03; Vol. 6 (4), pp. e2310039. <i>Date of Electronic Publication: </i>2023 Apr 03. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101729235 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2574-3805 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225743805%22">25743805 </searchLink><i>NLM ISO Abbreviation: </i>JAMA Netw Open <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37099295 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1001/jamanetworkopen.2023.10039 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e2310039 Titles: – TitleFull: Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bender Ignacio RA – PersonEntity: Name: NameFull: Chew KW – PersonEntity: Name: NameFull: Moser C – PersonEntity: Name: NameFull: Currier JS – PersonEntity: Name: NameFull: Eron JJ – PersonEntity: Name: NameFull: Javan AC – PersonEntity: Name: NameFull: Giganti MJ – PersonEntity: Name: NameFull: Aga E – PersonEntity: Name: NameFull: Gibbs M – PersonEntity: Name: NameFull: Tchouakam Kouekam H – PersonEntity: Name: NameFull: Johnsson E – PersonEntity: Name: NameFull: Esser MT – PersonEntity: Name: NameFull: Hoover K – PersonEntity: Name: NameFull: Neytman G – PersonEntity: Name: NameFull: Newell M – PersonEntity: Name: NameFull: Daar ES – PersonEntity: Name: NameFull: Fischer W – PersonEntity: Name: NameFull: Fletcher CV – PersonEntity: Name: NameFull: Li JZ – PersonEntity: Name: NameFull: Greninger AL – PersonEntity: Name: NameFull: Coombs RW – PersonEntity: Name: NameFull: Hughes MD – PersonEntity: Name: NameFull: Smith D – PersonEntity: Name: NameFull: Wohl DA IsPartOfRelationships: – BibEntity: Dates: – D: 03 M: 04 Text: 2023 Apr 03 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2574-3805 Numbering: – Type: volume Value: 6 – Type: issue Value: 4 Titles: – TitleFull: JAMA network open Type: main |
| ResultId | 1 |
